|
|
Post by aceton3 on Oct 31, 2018 11:45:18 GMT -5
It's not the earnings news that people are on the edge of their seats for...for now, it's everything else.
|
|
|
|
Post by prcgorman2 on Oct 31, 2018 14:43:35 GMT -5
There's no real reason to buy into earnings, MNKD has never popped because of earnings.
...yet.
To be fair, I think there was a "pop" (probably from algorithms?) for the "big" quarter which recognized revenue quarantined by very conservative accounting.
|
|
|
|
Post by peppy on Oct 31, 2018 15:16:44 GMT -5
MNKD Nasdaq real time volume, 1,097,439 shares. MNKD Nasdaq summary volume, 1,989,019 shares. MNKD $1.83. +0.05. +2.81% www.nasdaq.com/symbol/mnkd/real-timeThe 200 day just above price at $1.97.  |
|
|
|
Post by letitride on Oct 31, 2018 16:14:14 GMT -5
There's no real reason to buy into earnings, MNKD has never popped because of earnings. Now would be a good time to start; if you dont start you cant finish. Lets Go! |
|
|
|
Post by mytakeonit on Oct 31, 2018 16:39:00 GMT -5
POP !!! 5 cents !!!
|
|
|
|
Post by cedafuntennis on Oct 31, 2018 16:55:48 GMT -5
I am so worried about this pattern. While it normally should continue up, especially with the news we are expecting, the lack of such may make it roll-over and break all sorts of supports here. That would be my nightmare tonight...
|
|
|
|
Post by mango on Oct 31, 2018 17:37:09 GMT -5
MNKD Nasdaq real time volume, 1,097,439 shares. MNKD Nasdaq summary volume, 1,989,019 shares. MNKD $1.83. +0.05. +2.81% www.nasdaq.com/symbol/mnkd/real-timeThe 200 day just above price at $1.97. We look at monthly, weekly, daily. In that order. |
|
|
|
Post by mango on Oct 31, 2018 17:54:53 GMT -5
Daily...we zero in on this and its 1.83
200 day moving ave is lower than the daily. This means it is pointing up.
Peppy, how am I doing? 😆 😊
|
|
|
|
Post by mytakeonit on Oct 31, 2018 18:23:28 GMT -5
Peppy is on the side shaking her head ... maybe you should have said 100 day moving average or 50 day moving average instead. I say Up is Up !!!
kite is also on the side mumbling ... "I should have bought those 565,000 shares of MNKD" !!!
|
|
|
|
Post by xanet on Oct 31, 2018 18:42:56 GMT -5
I am so worried about this pattern. While it normally should continue up, especially with the news we are expecting, the lack of such may make it roll-over and break all sorts of supports here. That would be my nightmare tonight... I can't see it going below $1.50, and would be very surprised to see us go there anytime soon. My expectation is that our trading range will continue to creep upward, with higher lows and higher highs. I would be delighted to see us gap up on volume. We have seen sizable swings as we drifted on low volume. Let's see what high volume can do.... |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2018 19:01:44 GMT -5
I am so worried about this pattern. While it normally should continue up, especially with the news we are expecting, the lack of such may make it roll-over and break all sorts of supports here. That would be my nightmare tonight... Why? Several points to consider: Growing rx. Last week 365 renewals. Expect this to continue. Traction is in the house. Recent addition of $10m and $45m to balance sheet. With more to come in 2019. Getting cross company recognition. Yesterday's conference call at UTHR. Martine had nothing but positive words about MNKD and Technosphere (plus she's a Bruin). Next up RLS. Rumors of an RLS milestone payment. Deerfield is almost in the rearview mirror. There is possibility from UTHR to use other compounds on the platform. BAMM! Another $40m if you please. Finally, my own opinion. We have a drug that REALLY works in a very crowded diabetes space for sure. Yet. As the days, weeks, and months pass the idea of time in range takes hold. No other drug on the market can do what AFREZZA does. While it took Al's billions, Deerfield, a R/S etc, here we are. And although we are patent protected for years, what other pharma is going to be able to make a generic of Afrezza? They need the drug and the delivery device. Can you say multiple decades of NO competetion! If the thought of a generic scares anyone you should listen to Martine on UTHR's conference call yesterday. She acknowledged that generics were coming to market, however they dont have the same advantage as their brand. She gave several reasons for her opinion, please listen, very good stuff. She also stated clearly that prescribing physicians were weary of generics. While of course we are not out of the woods, a few more milestone payments, some warrants exercised, growing rx numbers; I would be very, very, cautious if I were shorting little ole MNKD. So, in conclusion if these drops in price will cause a nightmare situation, make lemonade. Considered it a Black Friday for MNKD stock. Cause, I can guarantee you that if things continue the way they are now, next year's share price will look a hell of lot different. |
|
|
|
Post by peppy on Oct 31, 2018 19:49:18 GMT -5
Daily...we zero in on this and its 1.83 200 day moving ave is lower than the daily. This means it is pointing up. Peppy, how am I doing? 😆 😊 End of the Month is a good time to look at the Monthly. In General the Monthly chart looks like Chit. The only thing we have here is a higher low, which happens to be what price needs to start a price turn around and we have that. Price - the gap has held. Price had an inside month. Looks like the 20 month equates with the 200 day presently at $1.97. It is an interesting fun fact that different moving averages on different time frames can equate.  Weekly, Moving in to observe price a little closer, Presenty MNKD price has made another wedge. (ON a higher low, with a very slow initiation gap.) Here we can see the wedge and when and where the price break above it will be. we are looking for this weekly wedge to pop and price to move up to $3.04 which is the top of this weekly wedge. The reason this chit works is the price pressure of sorts. Once price gets to three look Left. Price gets smacked in the head buy the Sanofi low at $3.20. When price gets to $3.20, looks like a possible right side of the inverted could have set up. That inverted looks like it will measure 2 dollars, which targets 5. price breaks 5 bucks looks like it could go to 15. with hard resistance at 8, the 2012 low.  Price has to pop out of this POS first. The 200 day = the 20 month. it always help to have the moving averages lined up. A prettier uptrend. The final destination target here top of the wedge can be seen on the monthly @ 35 dollars. Then we see. That's all I've got. Joey!  |
|
|
|
Post by prcgorman2 on Oct 31, 2018 23:02:17 GMT -5
I am so worried about this pattern. While it normally should continue up, especially with the news we are expecting, the lack of such may make it roll-over and break all sorts of supports here. That would be my nightmare tonight... Why? Several points to consider: Growing rx. Last week 365 renewals. Expect this to continue. Traction is in the house. Recent addition of $10m and $45m to balance sheet. With more to come in 2019. Getting cross company recognition. Yesterday's conference call at UTHR. Martine had nothing but positive words about MNKD and Technosphere (plus she's a Bruin). Next up RLS. Rumors of an RLS milestone payment. Deerfield is almost in the rearview mirror. There is possibility from UTHR to use other compounds on the platform. BAMM! Another $40m if you please. Finally, my own opinion. We have a drug that REALLY works in a very crowded diabetes space for sure. Yet. As the days, weeks, and months pass the idea of time in range takes hold. No other drug on the market can do what AFREZZA does. While it took Al's billions, Deerfield, a R/S etc, here we are. And although we are patent protected for years, what other pharma is going to be able to make a generic of Afrezza? They need the drug and the delivery device. Can you say multiple decades of NO competetion! If the thought of a generic scares anyone you should listen to Martine on UTHR's conference call yesterday. She acknowledged that generics were coming to market, however they dont have the same advantage as their brand. She gave several reasons for her opinion, please listen, very good stuff. She also stated clearly that prescribing physicians were weary of generics. While of course we are not out of the woods, a few more milestone payments, some warrants exercised, growing rx numbers; I would be very, very, cautious if I were shorting little ole MNKD. So, in conclusion if these drops in price will cause a nightmare situation, make lemonade. Considered it a Black Friday for MNKD stock. Cause, I can guarantee you that if things continue the way they are now, next year's share price will look a hell of lot different. Very nice positive post Georgthenite. I wish I could agree with the year from now prediction of the price per share. I think if things continue the way they are now, it will take more than a year. Afrezza sales are increasing, but the increase has been slow and nearly linear for about 1 year. It wasn't until the 2nd quarter of this year that we retraced to the levels of sales in the 4th quarter of last year. I hope next year doesn't show this is a repeating seasonal signature, but it might. The way things are going now is good in terms of Dr. Castagna having landed an important and valuable development agreement, and there may be more milestone payments as you mentioned. I do think predatory shorting by market makers seems less likely now because of high interest on loaned shares (although the interest on naked shorting is less, even that isn't without risk). The bottom-line remains the bottom line though and the main thing that will make the price per share look a heck of a lot different (in a good way) is significant sales of Afrezza. We're going to need that longed for "hockey stick" though to see sustained and substantial increase in stock price in less than 2 years. That's what makes the marketing story so important. Mannkind has done remarkably well with a shoestring staff and modest television advertising. Certainly there has been better performance when compared to the much larger expenditures (claimed) and salesforce of Sanofi. Debt has been managed so far without alarming dilution, but cash remains a concern so it's unclear if more significant marketing efforts are forthcoming. Refills and retention are improving and I continue to believe there will be a point of viral uptake because Afrezza is just that good, but I don't know what that point is, and I'm not sure we're close. I think things are definitely looking up as compared to 2016. I hope Dr. Castagna can continue the pace of improvements he's accomplished. If he can, then maybe you can happily tell me next year "I told you so" and I will be very glad to be told that. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2018 23:11:49 GMT -5
Why? Several points to consider: Growing rx. Last week 365 renewals. Expect this to continue. Traction is in the house. Recent addition of $10m and $45m to balance sheet. With more to come in 2019. Getting cross company recognition. Yesterday's conference call at UTHR. Martine had nothing but positive words about MNKD and Technosphere (plus she's a Bruin). Next up RLS. Rumors of an RLS milestone payment. Deerfield is almost in the rearview mirror. There is possibility from UTHR to use other compounds on the platform. BAMM! Another $40m if you please. Finally, my own opinion. We have a drug that REALLY works in a very crowded diabetes space for sure. Yet. As the days, weeks, and months pass the idea of time in range takes hold. No other drug on the market can do what AFREZZA does. While it took Al's billions, Deerfield, a R/S etc, here we are. And although we are patent protected for years, what other pharma is going to be able to make a generic of Afrezza? They need the drug and the delivery device. Can you say multiple decades of NO competetion! If the thought of a generic scares anyone you should listen to Martine on UTHR's conference call yesterday. She acknowledged that generics were coming to market, however they dont have the same advantage as their brand. She gave several reasons for her opinion, please listen, very good stuff. She also stated clearly that prescribing physicians were weary of generics. While of course we are not out of the woods, a few more milestone payments, some warrants exercised, growing rx numbers; I would be very, very, cautious if I were shorting little ole MNKD. So, in conclusion if these drops in price will cause a nightmare situation, make lemonade. Considered it a Black Friday for MNKD stock. Cause, I can guarantee you that if things continue the way they are now, next year's share price will look a hell of lot different. Very nice positive post Georgthenite. I wish I could agree with the year from now prediction of the price per share. I think if things continue the way they are now, it will take more than a year. Afrezza sales are increasing, but the increase has been slow and nearly linear for about 1 year. It wasn't until the 2nd quarter of this year that we retraced to the levels of sales in the 4th quarter of last year. I hope next year doesn't show this is a repeating seasonal signature, but it might. The way things are going now is good in terms of Dr. Castagna having landed an important and valuable development agreement, and there may be more milestone payments as you mentioned. I do think predatory shorting by market makers seems less likely now because of high interest on loaned shares (although the interest on naked shorting is less, even that isn't without risk). The bottom-line remains the bottom line though and the main thing that will make the price per share look a heck of a lot different (in a good way) is significant sales of Afrezza. We're going to need that longed for "hockey stick" though to see sustained and substantial increase in stock price in less than 2 years. That's what makes the marketing story so important. Mannkind has done remarkably well with a shoestring staff and modest television advertising. Certainly there has been better performance when compared to the much larger expenditures (claimed) and salesforce of Sanofi. Debt has been managed so far without alarming dilution, but cash remains a concern so it's unclear if more significant marketing efforts are forthcoming. Refills and retention are improving and I continue to believe there will be a point of viral uptake because Afrezza is just that good, but I don't know what that point is, and I'm not sure we're close. I think things are definitely looking up as compared to 2016. I hope Dr. Castagna can continue the pace of improvements he's accomplished. If he can, then maybe you can happily tell me next year "I told you so" and I will be very glad to be told that. Looking forward to that day prcgorman2. I believe sooner than you think. |
|
|
|
Post by cedafuntennis on Nov 1, 2018 0:53:51 GMT -5
I am so worried about this pattern. While it normally should continue up, especially with the news we are expecting, the lack of such may make it roll-over and break all sorts of supports here. That would be my nightmare tonight... Why? Several points to consider: Growing rx. Last week 365 renewals. Expect this to continue. Traction is in the house. Recent addition of $10m and $45m to balance sheet. With more to come in 2019. Getting cross company recognition. Yesterday's conference call at UTHR. Martine had nothing but positive words about MNKD and Technosphere (plus she's a Bruin). Next up RLS. Rumors of an RLS milestone payment. Deerfield is almost in the rearview mirror. There is possibility from UTHR to use other compounds on the platform. BAMM! Another $40m if you please. Finally, my own opinion. We have a drug that REALLY works in a very crowded diabetes space for sure. Yet. As the days, weeks, and months pass the idea of time in range takes hold. No other drug on the market can do what AFREZZA does. While it took Al's billions, Deerfield, a R/S etc, here we are. And although we are patent protected for years, what other pharma is going to be able to make a generic of Afrezza? They need the drug and the delivery device. Can you say multiple decades of NO competetion! If the thought of a generic scares anyone you should listen to Martine on UTHR's conference call yesterday. She acknowledged that generics were coming to market, however they dont have the same advantage as their brand. She gave several reasons for her opinion, please listen, very good stuff. She also stated clearly that prescribing physicians were weary of generics. While of course we are not out of the woods, a few more milestone payments, some warrants exercised, growing rx numbers; I would be very, very, cautious if I were shorting little ole MNKD. So, in conclusion if these drops in price will cause a nightmare situation, make lemonade. Considered it a Black Friday for MNKD stock. Cause, I can guarantee you that if things continue the way they are now, next year's share price will look a hell of lot different. We see the same about all the progress Dr. Castahna and his new team have developed put of the nothing left behind by the totally incompetent previous management. However, we are discussing MNKD here and the manipulation has been rampant and at tines made no sense but greed and desire to burry it. Tomorrow we'll see what will happen. I made a lot of lemonade during the past 4 years and the good people at MNKD, patients and all of us dedicated investors deserve this company to be around and be prosperous for many years to come. |
|
